2026 Interim Results

Uniphar posts strong H1 growth but rising debt and cash outflow flag execution risks.

What the company is saying

Uniphar plc frames its interim 2026 results as a period of strong growth, highlighting 6.9% organic gross profit growth and 11.2% adjusted EPS growth. The company emphasizes broad-based divisional performance, with Uniphar Pharma, Medtech, and Supply Chain & Retail all delivering reported gross profit growth between 7.0% and 9.0%. Management attributes the sharp increase in net bank debt (€275.7m, up from €171.1m in December 2025) and negative free cash flow conversion (-77.1%) to the expected unwind of prior-year working capital timing benefits, particularly in the Pharma division. The narrative is confident, with repeated references to being 'well positioned' for full-year EPS targets and an ambition to reach €200m EBITDA by 2028, underpinned by organic growth. The company also spotlights ongoing capital projects in Ireland, the Netherlands, and the UK, and sustainability initiatives such as a solar project for 2030 emissions targets. CEO Ger Rabbette leads the messaging, reinforcing confidence in divisional growth and strategic execution.

What the data suggests

The disclosed numbers show Uniphar delivered 7.2% revenue growth to €1,591.9m and 7.7% gross profit growth to €236.5m for H1 2026. Gross profit margin ticked up to 14.9%. Adjusted EPS rose 11.2% to 10.9 cent, and EBITDA increased 6.2% to €61.1m. Operating profit grew 8.6% to €35.4m, and the interim dividend was raised 4.2% to €0.0074 per share. Divisional gross profit growth was 7.0% for Pharma, 9.0% for Medtech, and 7.3% for Supply Chain & Retail, with the retail network expanding by 30 pharmacies to 512. Net bank debt jumped to €275.7m, leverage rose to 2.4x, and free cash flow conversion swung sharply negative (-77.1%), all explained as a reversal of prior working capital benefits. ROCE remained strong at 14.7%, within the 12%-15% target. The company is investing heavily in new facilities, with the Irish distribution center delayed to February 2027 and other projects completing in 2026. The data confirms strong operating momentum but also highlights rising leverage and cash flow pressure, with future benefits from capital projects still to be realized.

Analysis

The announcement presents a positive tone, supported by realised growth in revenue (+7.2%), gross profit (+7.7%), adjusted EPS (+11.2%), and operating profit (+8.6%) for the six months ended 30 June 2026. These are credible, measurable improvements, and the company discloses both top-line and profitability metrics. However, the narrative is inflated by repeated references to future benefits from ongoing capital projects (notably the new Irish distribution facility and solar project), which will not be operational until 2027 or later. The company highlights a significant increase in net bank debt (€275.7m, up from €171.1m) and negative free cash flow conversion (-77.1%), but frames these as temporary or strategic. Several forward-looking claims (e.g., EBITDA target of €200m by 2028, 'well positioned' for full-year EPS, and sustainability targets) are aspirational and not yet realised. The gap between narrative and evidence is moderate: while current financials are strong, the most ambitious claims relate to long-term, capital-intensive projects whose benefits are not imminent.

Risk flags

• ●Rising net bank debt and leverage (now at €275.7m and 2.4x) increase financial risk, especially as free cash flow conversion has turned sharply negative (-77.1%). If working capital does not normalize or profitability stalls, debt servicing could constrain flexibility.
• ●Execution risk is elevated for the new Irish distribution facility, which is delayed to February 2027 with a phased roll-out. Any further slippage or cost overruns could impact capacity expansion and the path to the €200m EBITDA target.
• ●The company's narrative relies on future benefits from capital-intensive projects and assumes continued organic growth. If market conditions change or integration of new facilities underperforms, the projected margin and earnings improvements may not materialize.
• ●Sustainability and emissions reduction initiatives are referenced but lack quantitative milestones or interim KPIs, making it difficult to assess progress or potential cost savings.
• ●The explanation for negative free cash flow conversion is attributed to working capital timing, but there is no detailed breakdown. If this is not a one-off effect, persistent cash outflows could undermine the investment case.

Bottom line

Uniphar's H1 2026 results show robust revenue, profit, and EPS growth, with all divisions contributing and margins stable or improving. The company is aggressively investing in new infrastructure, particularly in Ireland, aiming to double capacity and reach €200m EBITDA by 2028, with at least 80% of growth expected to be organic. However, leverage has risen sharply and free cash flow has turned negative, both flagged as temporary but representing real financial risk if not reversed. The timeline for major project benefits is at least 12–18 months away, and the company must execute flawlessly to deliver promised gains. Investors should focus on whether cash flow normalizes in H2 2026 and if project milestones are hit on schedule. The most important takeaway is that while operational momentum is strong, the investment case now hinges on managing debt, restoring positive cash flow, and delivering on large-scale capital projects without further delay or cost escalation.

Announcement summary

(LSE/AIM:CDI) Uniphar plc reported its 2026 interim results for the six months ended 30 June 2026, delivering 6.9% organic gross profit growth and 11.2% adjusted EPS growth. Group revenue increased to €1,591,855,000 from €1,485,492,000, representing 7.2% reported and 7.4% constant currency growth. Gross profit rose to €236,490,000 from €219,651,000, a 7.7% increase, with the gross profit margin improving to 14.9% from 14.8%. EBITDA grew by 6.2% to €61,059,000, and operating profit increased by 8.6% to €35,400,000. Net bank debt rose to €275,728,000 from €171,100,000 in December 2025, with leverage at 2.4x, mainly due to the expected unwind of prior year working capital timing benefits. The Board declared an interim dividend of €0.0074 per ordinary share, up 4.2% from €0.0071. Return on capital employed for the rolling 12-month period was 14.7%, within the Group's medium-term target of 12%-15%. The retail network expanded by 30 pharmacies to 512, and free cash flow conversion was negative 77.1% as at June 2026. The Group is completing state-of-the-art facilities in the Netherlands and UK in 2026, and a new high-tech distribution facility in Ireland will go live in February 2027 with a phased roll-out during H1 2027. Sustainability initiatives include a significant solar project supporting 2030 SBTi-aligned Scope 1 and 2 emissions reduction targets. The Group remains confident in achieving its €200,000,000 EBITDA target by 2028, with at least 80% of growth expected to be organic. A conference call for investors and analysts was held at 09:00 (BST) on 08 September 2026.

Disagree with this article?